Lurbinectedin (also known as PM01183) is an investigational drug that causes cancer cells to die by binding to and causing breaks in their DNA (genetic material). The drug has been shown to shrink or control tumor growth in patients with various cancer types, including cancers of the breast, lung, and ovaries.
Laboratory studies have shown that the drug paclitaxel, which has been used for many years to treat cancer, helps lurbinectedin to control cancer cell growth and to cause cancer cell death. In this study, researchers want to find the highest dose of lurbinectedin and paclitaxel that can be given together in patients with lung, ovarian, cervical, endometrial, breast, head and neck (squamous cell), or germ cell cancers, or adenocarcinoma of unknown primary. Both drugs are given intravenously (by vein).